Literature DB >> 819184

Enzymatic assay for methotrexate in serum and cerebrospinal fluid.

L C Falk, D R Clark, S M Kalman, T F Long.   

Abstract

We describe an assay for methotrexate in biological fluids. The assay is based on inhibition by methotrexate of dihydrofolate reductase from Lactobacillus casei. The lower limit of sensitivity in serum is 2 X 10(-8) mol (about 10 mug) of methotrexate per liter. Within-run precision is +/- 5% (coefficient of variation) and day-to-day variation is 18%. Advantages of the assay are ease of manipulation, high sensitivity, and specificity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 819184

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas.

Authors:  F M Balis; A Gillespie; J Belasco; G H Reaman; L J Ettinger; R F Murphy; K Doherty; S Jeffries; M E Horowitz; D G Poplack
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  A microbiological assay for the measurement of methotrexate in biological fluids.

Authors:  G C Icke; R E Davis; J Thom
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

3.  Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.

Authors:  R Goel; R Sanga; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Determination of methotrexate in biological fluids and a parenteral injection using terbium-sensitized method.

Authors:  Abolghasem Jouyban; Masoomeh Shaghaghi; Jamshid L Manzoori; Jafar Soleymani; Jalil Jalilvaez-Gharamaleki
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

5.  The effect of an anti-membrane antibody-methotrexate conjugate on the human prostatic tumour line PC3.

Authors:  A J Rowland; M E Harper; D W Wilson; K Griffiths
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.